title: Expression of a local immune defense system in the female genital tract. An immunohistochemical study.
abstract: The aim of this study was to investigate the presence of a local immunological defense mechanism of the secretory IgA class in the female genital tract.
  
  
  METHODS
  We studied by a streptavidin-biotin method the secretory component (SC) and IgA distribution in paraffin-embedded sections of 90 formalin-fixed specimens. We studied 10 normal and 5 neoplastic cervical specimens, 20 normal, 10 hyperplastic endometrial specimens and 10 endometrial adenocarcinomas, 5 normal ovarian tubes and 30 ovarian epithelial neoplasms, serous and mucinous. A polyclonal SC and (Dako) and a mab IgA (Dako) was used and the reaction was scored from 1-3.
  
  
  RESULTS
  Normal cervical mucosa and atrophic endometria were negative, while the basal portion of the endometrium, focally the proliferative glands, most of the secretory glands and most of the hyperplastic glands were positive for SC. IgA showed a similar distribution and a perivascular stromal reaction. Adenocarcinomas were positive for SC, but the intensity of the reaction was dependent on the differentiation of the tumors. Mucous and most serous neoplasms were negative for SC. IgA showed a similar reaction.
  
  
  CONCLUSIONS
  There is evidence that the female genital tract has a local defensive immune system that may be hormone dependent. SC is a valuable marker of glandular differentiation.
authors.affiliation: Pathology Department, Areteion Hospital, Athens University, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Kondi-Paphitis
authors.forename: H
authors.initials: H
authors.lastname: Carvounis
authors.forename: E
authors.initials: E
authors.lastname: Kairi
authors.forename: M
authors.initials: M
authors.lastname: Frangou
authors.forename: A
authors.initials: A
authors.lastname: Papayanopoulou
authors.forename: H
authors.initials: H
authors.lastname: Deligeorgi
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology; D016022:Case-Control Studies; D002584:Cervix Uteri / Q000276:immunology; D018284:Cystadenocarcinoma, Serous / Q000276:immunology; D018293:Cystadenoma, Serous / Q000276:immunology; D016889:Endometrial Neoplasms / Q000276:immunology; D005187:Fallopian Tubes / Q000276:immunology; D005260:Female; D005833:Genital Neoplasms, Female / Q000276:immunology*; D005836:Genitalia, Female / Q000276:immunology*; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000378:metabolism*; D007150:Immunohistochemistry; D010051:Ovarian Neoplasms / Q000276:immunology; D010053:Ovary / Q000276:immunology; D012635:Secretory Component / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000276:immunology
chemical_list: D007071:Immunoglobulin A, Secretory; D012635:Secretory Component